共查询到20条相似文献,搜索用时 31 毫秒
1.
2.
Impact of coronary artery calcification in percutaneous coronary intervention with paclitaxel‐eluting stents: Two‐year clinical outcomes of paclitaxel‐eluting stents in patients from the ARRIVE program 下载免费PDF全文
Michael S. Lee MD Tae Yang MD John Lasala MD David Cox MD 《Catheterization and cardiovascular interventions》2016,88(6):891-897
3.
Sebastian Kufner Steffen Massberg Michael Dommasch Robert A. Byrne Klaus Tiroch Sabine Ranftl Massimiliano Fusaro Albert Schmig Adnan Kastrati Julinda Mehilli 《Catheterization and cardiovascular interventions》2011,78(2):161-166
Background : In the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus‐Eluting Stents (ISAR‐TEST‐4) trial, we demonstrated the noninferiority of biodegradable polymer (BP) sirolimus‐eluting stent to permanent polymer (PP) sirolimus/everolimus‐eluting stent (Cypher/Xience‐V) on the basis of clinical outcomes. In this study, we compare the antirestenotic efficacy of these stents in ISAR‐TEST‐4 patients with paired angiographic studies. Methods : Patients with de novo coronary lesions in native vessels (excluding left main lesions) were randomly assigned to receive a BP stent or a PP stent. Endpoints of interest of this study were in‐stent late lumen loss, in‐segment binary restenosis, and restenosis morphology at 6–8‐month follow‐up angiogram. Results : Of the 2,603 patients (3,372 lesions) enrolled in ISAR TEST‐4 trial, 2,016 patients (2,637 lesions) underwent repeat angiographic examination 6–8 months after randomization: 1,006 patients (1,323 lesions) treated with BP stents and 1,010 patients (1,314 lesions) treated with PP stents. No difference was observed between BP and PP stents in in‐stent late lumen loss (0.24 ± 0.6 vs. 0.26 ± 0.5 mm, respectively, P = 0.49) or in in‐segment binary restenosis (11.6% [153 lesions] vs. 11.8% [155 lesions], P = 0.85). Focal pattern of restenosis was observed in the majority of patients receiving either BP or PP stents. The diffuse pattern of restenosis was observed in 26.8% of patients treated with BP stent and 26.5% of patients treated with PP stent (P = 0.79). Conclusion : Angiographic characteristics of restenosis after BP‐based limus‐eluting stents are similar to those of PP‐based limus‐eluting stents. © 2011 Wiley‐Liss, Inc. 相似文献
4.
5.
6.
7.
Backgrounds : Relative efficacy and safety of sirolimus‐eluting stents (SES) compared with paclitaxel‐eluting stents (PES) remains controversial. It is unknown whether there are different effect and safety in coronary bifurcation treatment between SES and PES. Objectives : The meta‐analysis was performed to compare the clinical outcomes of SES and PES in coronary bifurcation intervention. Methods : Five head‐to‐head clinical trials of SES versus PES in coronary bifurcation intervention were included. A total of 2,567 patients were involved in the meta‐analysis. Mean follow‐up period ranged from 6 to 35 months. The primary end points were the need for target lesion revascularization (TLR) and main‐branch restenosis. Secondary end points were target vessel revascularization (TVR), cardiac death, major adverse cardiac events (MACE), and stent thrombosis. Results : Compared with PES, SES significantly reduced the risk of TLR (5.3% vs. 10.6%, odds ratio (OR) 0.52; 95% confidence interval (CI) = 0.38–0.70, P < 0.001), main‐branch restenosis (4.59% vs. 12.59%, OR 0.31; 95% CI = 0.18–0.55, P < 0.001) and TVR (7.05% vs. 12.57%, OR 0.58; 95% CI = 0.42–0.81, P = 0.001) in coronary bifurcation intervention. In addition, SES group also had a significantly lower incidence of MACE (8.20% vs. 14.13%, OR 0.58; 95% CI = 0.40–0.84, P = 0.004) than PES group. However, there were no statistical difference with respect to the incidence of cardiac death (1.64% vs. 1.09%, P = 0.19) and stent thrombosis (0.84% vs. 1.08%, P = 0.64) between SES and PES groups. Conclusions : Compared with PES, SES reduced the incidence of TLR, main‐branch restenosis and MACE in coronary bifurcation intervention, while the risk of stent thrombosis was similar between SES and PES groups. © 2011 Wiley Periodicals, Inc. 相似文献
8.
Comparison of abluminal biodegradable polymer biolimus‐eluting stents and durable polymer everolimus‐eluting stents in the treatment of coronary bifurcations 下载免费PDF全文
Charis Costopoulos MD Azeem Latib MD Toru Naganuma MD Alessandro Sticchi MD Santo Ferrarello MD Damiano Regazzoli MD Alaide Chieffo MD Filippo Figini MD Mauro Carlino MD Matteo Montorfano MD Charbel Naim MD Masanori Kawaguchi MD Argyrios Gerasimou MD Francesco Giannini MD Cosmo Godino MD Antonio Colombo MD 《Catheterization and cardiovascular interventions》2014,83(6):889-895
9.
Long‐term safety and efficacy of second‐generation everolimus‐eluting stents compared to other limus‐eluting stents and bare metal stents in patients with acute coronary syndrome 下载免费PDF全文
Alfazir Omar MBChB Rebecca Torguson MPH Hironori Kitabata MD PhD Lakshmana K. Pendyala MD Joshua P. Loh MBBS Marco A. Magalhaes MD Lowell F. Satler MD William O. Suddath MD Augusto D. Pichard MD Ron Waksman MD 《Catheterization and cardiovascular interventions》2014,84(7):1053-1060
10.
Two‐year clinical outcomes of the NOBORI biolimus‐eluting stents versus XIENCE/PROMUS everolimus‐eluting stents in small vessel disease 下载免费PDF全文
Hiroyuki Jinnouchi MD Shoichi Kuramitsu MD Tomohiro Shinozaki MPH Takashi Hiromasa MD Yohei Kobayashi MD Takashi Morinaga MD Kyohei Yamaji MD Yoshimitsu Soga MD Shinichi Shirai MD Kenji Ando MD 《Catheterization and cardiovascular interventions》2016,88(5):E132-E138
11.
Sean M. Conte Daniel S. Florisson Joshua A. De Bono Peter R. Vale 《Internal medicine journal》2019,49(12):1534-1537
A best evidence topic was written addressing the question ‘in patients with saphenous vein graft lesions requiring percutaneous coronary intervention, do long‐term clinical outcomes differ between drug‐eluting and bare‐metal stents?’ Altogether 1466 papers were found, of which seven represented the best evidence. Although one major recent randomised trial was neutral, the weight of earlier evidence supports drug‐eluting stents as standard of care. Bare‐metal stents may represent a reasonable, efficacious, and less expensive alternative to drug‐eluting stents in well selected patient groups. 相似文献
12.
Moritz Baquet MD David Jochheim MD Julinda Mehilli MD 《Journal of interventional cardiology》2018,31(3):330-337
13.
Cihan Simsek MD Yoshinobu Onuma MD Michael Magro MD Sanneke de Boer MD Linda Battes MSc Ron T. van Domburg PhD Eric Boersma PhD Patrick W. Serruys MD PhD On Behalf of the Interventional Cardiologists of the Thoraxcenter 《Catheterization and cardiovascular interventions》2010,76(1):41-49
Background : There are limited data on the long‐term safety and efficacy profile of coronary stent implantation in patients with stable coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI). Objective : We aimed to assess the 4‐year clinical outcome in patients who received a bare‐metal stent (BMS), sirolimus‐eluting stent (SES), or a paclitaxel‐eluting stent (PES) for the percutaneous treatment of stable angina in our center during 2000–2005. Methods : In the study period, a total of 2,449 consecutive patients (BMS = 1,005; SES = 373; and PES = 1071) underwent a PCI as part of three historical PCI‐cohorts for stable angina and were routinely followed for the occurrence of major adverse cardiac events (MACE). Results : At 4 years follow‐up, 264 BMS patients (26.8%) had a MACE, compared to 75 SES patients (20.9%) and 199 PES patients (23.9%). Multivariate analysis showed that SES and PES were superior to BMS with respect to MACE [hazard ratio (HR) = 0.62, 95% confidence interval (CI): 0.47–0.81; HR = 0.67, 95% CI: 0.55–0.82, respectively]. The occurrence of MACE was significantly lower in the SES and PES population, primarily due to less target‐vessel revascularization (TVR) procedures (HR = 0.53, 95% CI: 0.37–0.75; HR = 0.71, 95% CI: 0.62–0.81, respectively). The occurrence of early, late, and very late stent thrombosis was equally rare with each stent type. There were no significant differences between SES and PES on death, myocardial infarction, TVR, and MACE. Conclusion : These findings suggest that SES and PES result in decreased TVR procedures and MACE compared to BMS at 4 years follow‐up. SES or PES implantation should be the preferred choice over BMS for patients with stable CAD undergoing PCI. © 2010 Wiley‐Liss, Inc. 相似文献
14.
Tarun Chakravarty MD Ryan P. Morrissey MD Brett Wertman MD Jesse Naghi MD Stanley Chou MD Pavel Goykhman MD Niraj Doctor MD James Mirocha MS James S. Forrester MD Raj Makkar MD 《Catheterization and cardiovascular interventions》2012,79(6):903-909
Objective : Our aim was to compare the long‐term outcomes between drug‐eluting stents and bare‐metal stents for saphenous vein graft stenosis. Background : The ideal type of stent to treat saphenous vein graft stenosis has not been clearly established. Short‐term randomized controlled trial results comparing drug‐eluting stents with bare‐metal stents for saphenous vein graft stenosis are conflicting, intermediate‐term retrospective studies and meta‐analyses at two years suggest no difference in outcomes, and there are no long term follow‐up studies. The need for long term follow‐up data has become emerged with concern over late stent thrombosis. Methods : 246 saphenous vein graft patients undergoing stenting from August 2002–December 2008 were studied. Overall survival and event‐free survival were compared by Kaplan‐Meier method. Hazard ratios (HR) were calculated by Cox‐proportional hazards models. Results : We treated 133 patients with DES (median follow‐up four years) and 113 patients with BMS (median follow‐up four years) for SVG stenosis. Overall survival (77.0% ± 3.9% vs. 70.6% ± 4.6%, log‐rank P = 0.60) and MACE‐free survival (57.5% ± 4.6% vs. 56.8% ± 4.9, log‐rank P = 0.70) were not significantly different between the DES and BMS groups. Although BMS was associated with increased risk of target lesion revascularization (TLR) (freedom from TLR 85.2% ± 3.5% vs. 90.0% ± 3.0%, HR 2.07, 95% CI 0.97–4.42, log‐rank P = 0.05), there was no significant difference in the freedom from myocardial infarction (86.7% ± 3.3% vs. 88.7% ± 3.2%, log‐rank P = 0.39) or target vessel revascularization (77.1% ± 4.2% vs. 76.1% ± 4.2%, log‐rank P = 0.33) between the two groups. Conclusions : Although mortality is not statistically different between DES and BMS for SVG stenosis, BMS is associated with increased risk of revascularization, thus suggesting the superiority of DES over BMS in the long term. © 2011 Wiley Periodicals, Inc. 相似文献
15.
16.
17.
18.
19.
Outcomes of small coronary artery stenting with bare‐metal stents versus drug‐eluting stents: Results from the NHLBI dynamic registry 下载免费PDF全文
Shailja V. Parikh MD Michael Luna MD Faith Selzer PhD Oscar C. Marroquin MD Suresh R. Mulukutla MD J. Dawn Abbott MD Elizabeth M. Holper MD MPH 《Catheterization and cardiovascular interventions》2014,83(2):192-200
20.
Cihan Simsek MD Michael Magro MD Eric Boersma PhD Yoshinobu Onuma MD Sjoerd Nauta MSc Gideon Valstar MSc Robert‐Jan van Geuns MD PhD Willem van der Giessen MD PhD Ron van Domburg PhD Patrick Serruys MD PhD Interventional Cardiologists of the Thoraxcenter 《Catheterization and cardiovascular interventions》2012,80(1):18-26
Background : There is few information on the long‐term efficacy and safety of sirolimus‐eluting stents (SES) and paclitaxel‐eluting stents (PES) compared to bare metal stents (BMS) in all‐comer percutaneous coronary intervention (PCI)—patients complicated by renal insufficiency (RI). Objective : Our aim was to assess the 6‐year clinical outcome of PCI‐patients with RI treated exclusively with BMS, SES, or PES in our academic hospital. Methods: A total of 1382 patients, included in three cohorts of consecutive PCI‐patients (BMS = 392; SES = 498; PES = 492), were categorized by creatinine clearance calculated by the Cockroft–Gault formula (normal kidney function ≥ 90; mild RI = 60–89; moderate RI < 60) and systematically followed for the occurrence of major adverse cardiac events (MACE). Results : Mortality rates were significantly higher for patients with moderate RI compared to mild RI and normal kidney function at 6 years (Kaplan–Meier estimate: moderate RI (34%) vs. mild RI (12%), P < 0.001; moderate RI (34%) vs. normal kidney function (8%), P < 0.001). After multivariate Cox‐regression analysis, SES and PES decreased the occurrence of target‐vessel revascularization (TVR) and MACE at 6 years in patients with a normal creatinine clearance compared to BMS [adjusted hazard ratio (aHR) = 0.48, 95% CI: 0.28–0.84; aHR = 0.75, 95% CI: 0.57–0.97, respectively] with no significant effect on mortality. Safety‐ and efficacy end points were comparable for the three stent types in patients with mild‐ and moderate renal function. Conclusion : Patients with a normal creatinine clearance had significant improvement in TVR and MACE rates after SES‐ or PES implantation compared to BMS at 6 years. However, there was no superiority of both drug‐eluting stents over BMS in safety and efficacy end points for patients with impaired renal function. © 2012 Wiley Periodicals, Inc. 相似文献